Your browser doesn't support javascript.
loading
Discovery and Characterization of a Pan-betacoronavirus S2-binding antibody.
Johnson, Nicole V; Wall, Steven C; Kramer, Kevin J; Holt, Clinton M; Periasamy, Sivakumar; Richardson, Simone; Suryadevara, Naveenchandra; Andreano, Emanuele; Paciello, Ida; Pierleoni, Giulio; Piccini, Giulia; Huang, Ying; Ge, Pan; Allen, James D; Uno, Naoko; Shiakolas, Andrea R; Pilewski, Kelsey A; Nargi, Rachel S; Sutton, Rachel E; Abu-Shmais, Alexandria A; Parks, Robert; Haynes, Barton F; Carnahan, Robert H; Crowe, James E; Montomoli, Emanuele; Rappuoli, Rino; Bukreyev, Alexander; Ross, Ted M; Sautto, Giuseppe A; McLellan, Jason S; Georgiev, Ivelin S.
Afiliação
  • Johnson NV; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Wall SC; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Kramer KJ; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN 73232, USA.
  • Holt CM; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Periasamy S; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN 73232, USA.
  • Richardson S; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Suryadevara N; Program in Chemical and Physical Biology, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Andreano E; Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Paciello I; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Pierleoni G; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
  • Piccini G; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.
  • Huang Y; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Ge P; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
  • Allen JD; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
  • Uno N; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
  • Shiakolas AR; VisMederi Research S.r.l., Siena 53100, Italy.
  • Pilewski KA; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
  • Nargi RS; Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Sutton RE; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
  • Abu-Shmais AA; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
  • Parks R; Department of Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44196, USA.
  • Haynes BF; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
  • Carnahan RH; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Crowe JE; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN 73232, USA.
  • Montomoli E; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Rappuoli R; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN 73232, USA.
  • Bukreyev A; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Ross TM; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • Sautto GA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
  • McLellan JS; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN 73232, USA.
  • Georgiev IS; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
bioRxiv ; 2024 Jan 16.
Article em En | MEDLINE | ID: mdl-38293237
ABSTRACT
Three coronaviruses have spilled over from animal reservoirs into the human population and caused deadly epidemics or pandemics. The continued emergence of coronaviruses highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using LIBRA-seq, we report a panel of 50 coronavirus antibodies isolated from human B cells. Of these antibodies, 54043-5 was shown to bind the S2 subunit of spike proteins from alpha-, beta-, and deltacoronaviruses. A cryo-EM structure of 54043-5 bound to the pre-fusion S2 subunit of the SARS-CoV-2 spike defined an epitope at the apex of S2 that is highly conserved among betacoronaviruses. Although non-neutralizing, 54043-5 induced Fc-dependent antiviral responses, including ADCC and ADCP. In murine SARS-CoV-2 challenge studies, protection against disease was observed after introduction of Leu234Ala, Leu235Ala, and Pro329Gly (LALA-PG) substitutions in the Fc region of 54043-5. Together, these data provide new insights into the protective mechanisms of non-neutralizing antibodies and define a broadly conserved epitope within the S2 subunit.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos